GSKGSK plc

NYSE gsk.com


$ 41.29 $ 0.27 (0.65 %)    

Friday, 16-Aug-2024 15:59:56 EDT
QQQ $ 475.24 $ 0.61 (0.13 %)
DIA $ 406.80 $ 0.86 (0.21 %)
SPY $ 554.24 $ 1.24 (0.22 %)
TLT $ 97.41 $ 0.34 (0.35 %)
GLD $ 231.90 $ 5.08 (2.24 %)
$ 41.28
$ 41.29 x 200
$ 41.30 x 300
-- - --
$ 32.11 - $ 45.37
3,145,786
na
89B
$ 0.52
$ 14.17
TBD
na
na ($ 0.05)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 florida-ruling-upholds-gsks-stance-on-once-popular-heart-burn-drug-zantac-not-being-associated-with-cancer-risk

A Florida State Court sided with GSK, dismissing expert testimonies that linked ranitidine to prostate cancer, reflecting a bro...

 new-european-regulations-could-hinder-rare-disease-treatments-pharma-industry-raises-concerns-over-stricter-clinical-trial-rules

Pharmaceutical companies, researchers, and patient groups are voicing concerns over new EU regulations that could hinder rare d...

 moderna-stock-trading-lower-on-dismal-guidance-analysts-cuts-price-targets-noting-competitive-pressure-from-gsk-pfizer

Moderna cuts its 2024 sales forecast due to weaker demand for COVID-19 vaccines. Sales now expected between $3B-$3.5B, down fro...

 gsks-dostarlimab-gxly-fda-indication-expanded-for-endometrial-cancer-with-chemotherapy

- Reuters 

 tech-stocks-on-track-for-best-session-in-5-months-ahead-of-fed-meeting-small-caps-target-highest-close-since-january-2022-whats-driving-markets-wednesday

Tech stocks soared to their best session in five months on Wednesday, ahead of the highly anticipated Federal Open Market Commi...

 british-pharma-giant-gsks-blockbuster-shingles-and-respiratory-syncytial-virus-vaccine-q2-sales-miss-expectations-cuts-annual-vaccine-revenue-guidance

GSK reported Q2 sales of $9.95 billion, beating estimates of $9.66 billion. Specialty Medicine sales rose 20%, driven by strong...

 wall-street-remains-on-track-for-amd-led-rebound-ahead-of-fed-decision-meta-earnings-analyst-says-the-bull-tends-to-remain-despite-near-term-volatility

Tech optimism is likely to abound on Wall Street as AI-levered stocks are feeding off the strength generated by Advanced Micro ...

 gsk-and-flagship-pioneering-to-invest-150m-in-innovative-health-solutions

GSK plc (NYSE:GSK) and Flagship Pioneering (Flagship), the bioplatform innovation company, today announced they have entered a ...

 apple-amazon-microsoft-meta-lead-the-charge-as-investors-bank-on-tech-cheer-for-rallys-reacceleration-week-ahead-in-earnings

The unfolding week's market trajectory depends on earnings from bellwether tech stocks and what the Fed has to say followin...

 gsks-top-selling-vaccine-can-potentially-reduce-dementia-risk-research-suggests

New research suggests that GSK's Shingrix vaccine may reduce dementia risk, potentially revolutionizing treatment for older...

 pfizer-and-gsks-viiv-healthcares-two-drug-hiv-treatment-matches-gileads-three-drug-combo-in-major-trial

ViiV Healthcare's Dovato matches Gilead's Biktarvy in effectiveness for HIV treatment. The study reveals Dovato's b...

 european-commission-faces-court-criticism-over-covid-vaccine-contract-transparency-ahead-of-vote-on-ursula-von-der-leyens-reappointment

European Commission faces scrutiny over COVID vaccine contract transparency ahead of key vote. Legal challenges and implication...

 gsk-begins-shipping-influenza-vaccine-doses-for-2024-25-season-expects-to-distribute-over-36m-doses-of-its-trivalent-influenza-vaccines-in-the-us-this-season

GSK supports annual flu immunization by getting FLULAVAL and FLUARIX to patients in advance of flu seasonGSK plc (NYSE:GSK) tod...

 health-officials-keep-close-eye-on-bird-flu-as-it-infects-cows-for-the-first-time

Avian influenza continues to spread among animals and has infected four dairy workers in the US. Concerns about human-to-human ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION